Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
With
Radiation Therapy Oncology Group
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must have a clinical diagnosis of glioblastoma (GBM).
Must have a confirmed epidermal growth factor receptor amplification in tumor tissue.
Must have a Karnofsky Performance Status (KPS) \>= 70 at assessment \<= 14 days prior to randomization (N/A to the sub-study).
Must have recovered from effects of surgery, postoperative infection and other complications of surgery.
Must have adequate bone marrow, renal, and hepatic function (For the sub-study, the participant must have adequate bone marrow and renal function and have mild-to-moderate hepatic impairment).
You may not be if
Multifocal, recurrent or metastatic GBM or gliomatosis cerebri (For the sub-study, the participant can have multifocal GBM and glimatosis cerebri but can't have recurrent or metastatic GBM).
Prior chemo therapy or radiosensitizer for head and neck cancer.
Prior radiotherapy to the head or neck in overlap of radiation fields.
Prior therapy for glioblastoma or other invasive malignancy.
Prior, concomitant or planned treatment with Novo Tumor Treatment Fields (Novo-TTF), EGFR-targeted therapy, bevacizumab, Gliadel wafers or other intratumoral or intracavity anti-neoplastic therapy.
Clareo Health | A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
